Following PBL incubation with DiD-loaded LNCs, maximum LNC internalization was observed by total monocytes (CD14+ cells: 83.0 ± 6.4%) and by monocyte subsets CD14+ HLA-DRlow (86.4 ± 8.2%) and CD14+ IL4Rα+ (84.7 ± 6.9%) cells, corresponding to monocytic MDSCs (Fig. 3a), thus highlighting that this nanocarrier system could efficiently target immunosuppressive myeloid cells in GBM patients, while sparing lymphocyte subsets that, instead, showed very low uptake. This evidence concerns the gene IL4R and glioblastoma.